OT 1 9 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Chang, Xiao-Jia

Art Unit; 1641

Serial No:

10/615,343

Examiner: Grun, James Leslie

Filed:

July 8, 2003

Attorney Docket No.: IGA-003.01

For: Methods of Producing Antibodies for Diagnostics and Therapeutics

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 17, 2005.

Shirine Darvish

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BASED ON INTERNATIONAL SEARCH REPORT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicant hereby makes of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of non-U.S. patent publications and documents (References C1-C5) are enclosed.

Applicant has listed dates of publication on the attached Form PTO-1449 for the cited documents based on information presently available to the undersigned. However, the listed publication dates should not be construed as indicating that the information in the cited documents was actually published or otherwise publicly available on the date indicated.

Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached Form PTO-1449.

Page 2 USSN 10/884,879

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that each or all of the listed documents are material or constitute "prior art." Further, if the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents. Moreover, the Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

It is believed that no fees are incurred by this submission. However, if any additional fees are due, the Commissioner is hereby authorized to charge any deficiencies or credit any overpayment to Deposit Order Account No. 06-1448.

Should there be any questions after reviewing this paper, the Examiner is invited to contact the undersigned at (617) 832-1000.

Respectfully submitted,

mann all

FOLEY HOAG LLP

By:

Janann Reg. No. 54,958

Agent for Applicant

Dated: October 17, 2005 Customer No.: 25181

Patent Group Foley Hoag LLP 155 Seaport Boulevard Boston, MA 02210-2600 Telephone: (617) 832-1000

Facsimile: (617) 832-7000

								Sheet Pa	ge 1 of 3
Form PTO 1449 O PORMATION DISCLOSURE CITATION AN APPLICATION (Use several sheets if necessary)					et Number (Optional) O P E	Application Number 10/615,343			
					cant g, Xiao-Jia				
OCT 19 700° E				Filing		Group Art Unit 1641			
OLITA	#/				S. PATENT QOCUMENTS				
NEXAMINER OF THE PROPERTY OF T	MINER DOCUMENT NUMBER DAT			THAM HENDE		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
								<u> </u>	
		•]	FORE	EIGN PATENT DOCUMENT	S			
	DOCUMENT NUMBER DA			ATE COUNTRY		CLASS SUBCLASS		Translation YES NO	
	Cı	03/012105 A	02/13/	/03	WIPO				
OTHER DO					UMENTS (Including Author, Title, Date, Pertinent Pages Etc.)				c.)
	C2	Herrera-Gayol A. et Pathology 1999 66(proteins in the biology of breast ca	ancer: contributi	on of CD44",	Exp. and Mo	ol.		
	C3	Wittig B. et al., "Curative treatment of an experimentally induced colitis by a CD44 varian V7-specific antibody!", J. Immunol. 1998 161(3):1069-1073							
	C4								
	C5								
							, , , , , , , , , , , , , , , , , , , ,		
EXAMINER							•		
EXAMINER:	Initi	ial if citation considered	whether	or not o	citation is in conformance with MPEP	§ 609; Draw line	through citation	if not in	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not ir conformance and not considered. Include copy of this form with next communication to the applicant.